title: Common Drugs for Stabilization of Renal Function in the Progression of Diabetic Nephropathy and Their Relations with Hypertension Therapy.
abstract: BACKGROUND
  Diabetic nephropathy is characterized by hypertension, progressive albuminuria, glomerulosclerosis and declines in glomerular filtration rate leading to end stage renal disease. Although the pathogenesis of diabetic nephropathy is not fully understood, current treatment of the patients with diabetic nephropathy is mainly based upon the control of hyperglycaemia and management of blood pressures.
  
  
  BACKGROUND
  Several drugs, which are originally developed for hypertension therapy, have been adopted for stabilization of renal function in diabetic nephropathy. In this review, we first discussed the relationships between diabetic nephropathy and hypertension particularly in the renin-angiotensinaldosterone system. We then summarized chemical structures, pharmacological characteristics and clinical studies of the common drugs used for treatment of diabetic nephropathy, while these drugs have effects against hypertension.
  
  
  CONCLUSIONS
  This review may provide the constructive information for further drug development in diabetic nephropathy.
authors.affiliation: School of Life Science and Technology, China Pharmaceutical University, Nanjing, 210009, China.
authors.forename: Yuxuan
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.|School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Nephrology, Benxi Center Hospital, China Medical University, Benxi, 117000, China.|Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, 17176, Sweden.
authors.forename: Xiuli
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Center for Molecular Medicine, Karolinska Institutet, Karolinska University Hospital, Solna, Stockholm, 17176, Sweden.|Department of Clinical Science, Intervention and Technologies, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, 14157, Sweden.
authors.forename: Harvest F
authors.initials: HF
authors.lastname: Gu
authors.affiliation: Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing, 210009, China.
authors.forename: Liang
authors.initials: L
authors.lastname: Wu
mesh_terms: D000419:Albuminuria / Q000150:complications; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology; D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003928:Diabetic Nephropathies / Q000150:complications / Q000503:physiopathology*; D018450:Disease Progression; D005919:Glomerular Filtration Rate; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D007676:Kidney Failure, Chronic / Q000503:physiopathology*; D012084:Renin-Angiotensin System / Q000187:drug effects
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents
keywords: ACE inhibitor; Diabetic nephropathy; angiotensin; hypertension; renal function; renin-angiotensin-aldosterone system